THE MINISTER OF HEALTH AND FAMILY WELFARE
(DR. MANSUKH MANDAVIYA)
(a) to (e) A Statement is laid on the Table of the House.
STATEMENT REFERRED TO IN REPLY TO LOK SABHA
STARRED QUESTION NO. 94* FOR 3RD DECEMBER, 2021
(a) to (e) A total of 51,775 cases of Mucormycosis have been reported till 29th November 2021. State wise cases of Mucormycosis reported till 29th November 2021 are at Annexure 1.
Further, 28 cases have been reported in Prayagraj, UP & 2 cases of Mucormycosis are reported in Jamui, Bihar.
Health is a state subject. Union Ministry of Health has proactively supported states to tackle the challenge posed by cases of Mucormycosis during the second surge of Covid-19.
MOHFW had asked all states vide DO letter dated 19th May and 24th May to make Mucormycosis a notifiable disease so as get details of Mucormycosis incidence in the country. A unified portal was created by MoHFW for States to enter surveillance data of Mucormycosis cases.
The Ministry of Health & Family Welfare has issued national comprehensive guidelines for the management of post covid sequelae including mucormycosis as available on
https://www.mohfw.gov.in/pdf/NationalComprehensiveGuidelinesforManagementofPostCovidSequelae.pdf.
The clinical management guidelines for managing COVID-19 cases by Ministry of Health & Family Welfare advocates rational use of steroids for managing moderate to severe cases of COVID-19 under strict medical supervision. Further noting relationship between use of steroids and other immune-suppressive drugs “Advisory for rational use of Steroids and Tocilizumab in the treatment of Covid -19 patients” was issued by Directorate General of Health Services.
Since early May, 2021 the details of production, stock, supplies made and purchase orders were obtained from the manufacturers and their co-operation was sought to overcome the gap between supply and demand.
Department of Pharmaceuticals (DoP), Central Drugs Standard Control Organisation (CDSCO) & National Pharmaceutical Pricing Authority (NPPA) have been jointly monitoring the production and availability of critical (COVID) drugs including Amphotericin-B injections.
Central Government has placed Amphotericin B under restricted category for export vide Notification dated 1st June, 2021 for ensuring continuous availability of medicines for treatment of Mucormycosis cases domestically.
Central Government has undertaken steps to procure the Amphotericin-B from various available sources around the globe and made efforts to increase the production of existing Manufacturers/Importers for the said drug in the country.
Central Drugs Standard Control Organisation (CDSCO) under MoHFW has given permission to 11 new manufacturers of Liposomal Amphotericin- B. A total of 16,08,291 vials of Liposomal Amphotericin-B were jointly allocated by Dept. of Pharmaceuticals and MoHFW to various States/UTs up to 24th July 2021 on commercial basis.
Further, 3 lakhs vials of Liposomal Amphotericin–B procured by MoHFW has been allocated to States/UTs and Central Health Institutions free of cost.
Ministry of External Affairs (MEA) contacted various manufacturers abroad. Through its missions all over the world, MEA has identified new sources of Amphotericin B/ Liposomal Amphotericin B injections and alternative drugs for treatment of Mucormycosis.
For equitable distribution, allotments have been made to the States/ UTs in accordance with the proportion of their reported case load in respect of the entire country.
Supply arrangements have been monitored by the National Pharmaceuticals Pricing Authority (NPPA) so as to ensure expeditious availability of the drug.
NPPA has put in place a strongly responsive system to ensure timely supplies of allocated volumes and maintains continuous contact with States/UTs and suppliers to trouble shoot any issues in reaching the drugs to the Health Departments of States/ UTs.
Both first- and second-line drugs used for managing Mucormycosis cases i.e. Amphotericin B Deoxycholate and Posaconazole are currently amplyavailable in Indian markets
During 2021(as on 21stNovember) total number of 1,64,103 dengue cases were reported as against 2,05,243 cases in 2019. Through the efforts of Government of India and States the Case Fatality Rate (deaths per 100 cases) has been sustained
Download PDF Files
